Tremtelectogene empogeditemcel is under clinical development by Vor BioPharma and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase II drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tremtelectogene empogeditemcel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tremtelectogene empogeditemcel overview
Trem-cel (VOR-33) is under development for the treatment of relapsed and refractory acute myeloid leukemia (AML), myelodysplastic syndrome and myeloproliferative neoplasm . It is administered via parenteral route. The therapeutic candidate comprises allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC).It is developed based on eHSC technology.
Vor BioPharma overview
Vor BioPharma, a subsidiary of Puretech Health Plc, is a clinical-stage cell therapy company that develops therapies for the treatment of hematological malignancies. The company’s pipeline products include Trem-cel (formerly VOR33), is an eHSC product candidate created by genetically modifying healthy donor HSCs in order to remove the CD33 surface target protecting them from a targeted therapy post-transplant. Vor BioPharma‘s other pipelines include VCAR33 (Allogeneic), VCAR33 (Autologous), Trem-cel + VCAR33, Treatment System and CD33-CLL1 Treatment System. Vor BioPharma is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Tremtelectogene empogeditemcel’s drug-specific PTSR and LoA scores, buy the report here.